ArticleFrontiers in nutrition2022
Probiotic Therapy With VSL#3
Article in Frontiers in nutrition, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 4 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- The impact of dietary interventions on liver health biomarkers in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic literature review and meta-analysis of randomized controlled trials.European journal of nutrition · 2026Pooled it
- Effects of probiotics and synbiotics on liver enzymes, glucose and lipid metabolism, and inflammatory markers in patients with metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis.Frontiers in nutrition · 2026Pooled it
- Efficacy of probiotics, prebiotics, and synbiotics on liver enzymes, lipid profiles, and inflammation in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials.BMC gastroenterology · 2024Pooled it
- The effect of gut microbiome-targeted therapies in nonalcoholic fatty liver disease: a systematic review and network meta-analysis.Frontiers in nutrition · 2024Pooled it
- Effect of synbiotic supplementation on immune parameters and gut microbiota in healthy adults: a double-blind randomized controlled trial.Gut microbes · 2023Trial
- VSL#3 Co-Administration Is Associated with Altered Early-Phase Obeticholic Acid Exposure in MASLD Mice.Nutrients · 2026Article
- Decoding the mechanistic basis of liver-muscle communication in health and disease.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Nfil3 integrates circadian rhythm and microbial metabolite signaling to maintain gut-liver immune-metabolic homeostasis under high-fat diet stress.Journal of translational medicine · 2026Article
- Advances in the acting mechanism and treatment of gut microbiota in metabolic dysfunction-associated steatotic liver disease.Gut microbes · 2025Review
- Gut microbiota diversity and metabolomics analysis of curcumin's alleviation of abdominal aortic aneurysm progression.Molecular and cellular biochemistry · 2025Article
- Intestinal Microbiota Modulation by Fecal Microbiota Transplantation in Nonalcoholic Fatty Liver Disease.Biomedicines · 2025Review
- Application of probiotic therapy in nonalcoholic fatty liver disease: mediating mechanism and future perspective.Frontiers in cellular and infection microbiology · 2025Review
- Probiotics as a therapeutic strategy for metabolic dysfunction-associated steatotic liver disease: A systematic review and meta-analysis.Current research in food science · 2025Review
- Review
- Updated Insights into Probiotics and Hepatobiliary Diseases.Biomedicines · 2024Review
- Probiotics, prebiotics, and synbiotics in nonalcoholic fatty liver disease and alcohol-associated liver disease.American journal of physiology. Gastrointestinal and liver physiology · 2023Review
- Intestinal Barrier Function in the Pathogenesis of Nonalcoholic Fatty Liver Disease.Journal of clinical and translational hepatology · 2023Review
- Fecal Microbiota Transplantation in NAFLD Treatment.Medicina (Kaunas, Lithuania) · 2022Review
- Interplay between metabolic dysfunction-associated fatty liver disease and chronic kidney disease: Epidemiology, pathophysiologic mechanisms, and treatment considerations.World journal of gastroenterology · 2022Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: To evaluate if VSL#3 Methods: We enrolled 60 Caucasian patients aged ≥ 18 years of either sex with the diagnosis of non-alcoholic fatty liver disease (NAFLD), according to practice guidance, in a double-blind, placebo-controlled study. Patients were randomized to take placebo or VSL#3 Results: We did not observe any change in body mass index (BMI), circumferences, fasting plasma glucose (FPG), total cholesterol (TC), low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein-cholesterol (HDL-C), and adiponectin (ADN) with neither treatment. A statistically significant triglycerides (Tg) decrease ( Conclusion: Probiotic therapy with VSL#3
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.